Online Sale of Unregulated SARMs Endangers India's Youth

A recent investigation conducted by India's National Anti‑Doping Agency has revealed that a substantial proportion of adolescents and young adults, particularly those between sixteen and twenty‑five years of age, are repeatedly exposed to advertisements for unapproved selective androgen receptor modulators on popular social‑media platforms.

These substances, colloquially marketed as performance enhancers yet lacking rigorous clinical validation, have been linked in medical literature to hepatic toxicity, endocrine disruption, and cardiovascular compromise, thereby posing a grave, largely concealed threat to the physiological development of the nation's burgeoning demographic.

In response, the Ministry of Health and Family Welfare, through its Food Safety and Standards Authority, has issued advisories cautioning consumers while simultaneously acknowledging the limited capacity of existing regulatory frameworks to monitor the rapid diffusion of digital marketplaces.

The phenomenon disproportionately afflicts economically disadvantaged youths, for whom the allure of inexpensive, ostensibly potent body‑building aids supersedes the meager access to certified sports‑science guidance, thereby exacerbating entrenched inequalities in health outcomes and educational attainment.

Given this confluence of commercial predation, regulatory lag, and vulnerable consumer bases, one must inquire whether the present legislative architecture, particularly the Drugs and Cosmetics Act as amended, possesses sufficient granularity to classify and prohibit synthetic SARMs marketed solely through encrypted channels, whether the inter‑agency coordination between the Cyber Cell of the Central Bureau of Investigation and the Directorate General of Health Services is equipped with the technical expertise and resources to trace and dismantle transnational supply chains that exploit India’s digital economy, whether the existing public‑health communication strategies are capable of penetrating vernacular networks to replace allure with evidence‑based counsel, and whether the judiciary, when confronted with burgeoning civil suits filed by families of afflicted youths, will demand demonstrable accountability from manufacturers, distributors, and platform operators rather than merely issuing procedural injunctions, or whether the state‑funded research institutions will be mandated to disseminate longitudinal studies quantifying the morbidity associated with unsupervised SARM consumption, thereby furnishing policymakers with empirical foundations for future statutory revisions.

In light of these considerations, the chronic question emerges whether the parliamentary committees tasked with overseeing sports and health portfolios will initiate a comprehensive inquiry into the nexus between illicit performance‑enhancing drugs and the nation's educational institutions, whether the Right‑to‑Information provisions will be invoked to compel disclosure of all pending investigations pertaining to online SARM commerce, whether the emerging body of jurisprudence on consumer protection in the digital arena will evolve to recognize psychological coercion as a substantive form of injury warranting compensation, and whether the citizenry, empowered by civil‑society watchdogs, will secure a binding mandate compelling the government to allocate dedicated resources toward a national awareness campaign that integrates school curricula, community health workers, and digital literacy programs to counteract the seductive narratives propagated by illicit vendors, as well as instituting a transparent mechanism for periodic reporting on enforcement outcomes to assure the public that judicial pronouncements are not merely ceremonial.

Published: May 11, 2026